Heart transplantation: assessment of heart failure mortality risk.

Curr Heart Fail Rep

Division of Cardiovascular Medicine, University of Michigan Medical Center, Women's L3623, Ann Arbor, MI 48109-0271, USA.

Published: June 2007

Heart failure (HF) presents with a wide spectrum of disease severity and with a broad risk of associated morbidity and mortality. Identification of individuals at high risk for HF death is important for assessment of candidacy for heart transplantation and mechanical circulatory assistance and, more broadly, for guiding pharmaceutical, surgical, or palliative interventions. In this article, we review and compare several of the HF risk prediction tools currently available, highlighting their clinical utilities and potential shortcomings. Risk prediction tools must be carefully selected, recognizing that their accuracy is likely to be greatest when used in patients most similar to those from whom the tool was developed. As HF is a dynamic condition, serial risk assessment at regular intervals and as patient clinical status changes is warranted, although clinical evidence to support this practice is limited.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11897-007-0008-3DOI Listing

Publication Analysis

Top Keywords

heart transplantation
8
heart failure
8
risk prediction
8
prediction tools
8
risk
6
heart
4
transplantation assessment
4
assessment heart
4
failure mortality
4
mortality risk
4

Similar Publications

Background: Patients with end-stage kidney disease (ESKD) are at high risk for coronary artery disease. We investigate the trends and outcomes of percutaneous coronary intervention (PCI) for stable ischemic heart disease (SIHD) in patients with ESKD.

Methods: We utilized the United States Renal Data System [2010-2018] to include adult patients with ESKD on dialysis for at least 3 months who underwent PCI for SIHD.

View Article and Find Full Text PDF

Introduction: Organ transplant recipients face a substantial risk of developing posttransplant lymphoproliferative disorders (PTLD). In over 90% of cases with B-cell PTLD following solid organ transplantation, the Epstein-Barr virus (EBV) genome is promptly identified, usually within the initial year. A continuing discussion revolves around the efficacy of antiviral prophylaxis in mitigating the incidence of PTLD in solid organ transplant (SOT) patients.

View Article and Find Full Text PDF

Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.

Nat Med

January 2025

Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.

Allogeneic chimeric antigen receptor (CAR) T cells targeting disialoganglioside-GD2 (ALLO_GD2-CART01) could be a therapeutic option for patients with relapsed or refractory, high-risk neuroblastoma (r/r HR-NB) whose tumors did not respond to autologous GD2-CART01 or who have profound lymphopenia. We present a case series of five children with HR-NB refractory to more than three different lines of therapy who received ALLO_GD2-CART01 in a hospital exemption setting. Four of them had previously received allogeneic hematopoietic stem cell transplantation.

View Article and Find Full Text PDF

The highly conserved PIWI-interacting RNA CRAPIR antagonizes PA2G4-mediated NF110-NF45 disassembly to promote heart regeneration in mice.

Nat Cardiovasc Res

January 2025

Department of Pharmacy at the Second Affiliated Hospital, and Department of Pharmacology at College of Pharmacy (The Key Laboratory of Cardiovascular Research, Ministry of Education; National Key Laboratory of Frigid Zone Cardiovascular Diseases), Harbin Medical University, Harbin, China.

Targeting the cardiomyocyte cell cycle is a promising strategy for heart repair following injury. Here, we identify a cardiac-regeneration-associated PIWI-interacting RNA (CRAPIR) as a regulator of cardiomyocyte proliferation. Genetic ablation or antagomir-mediated knockdown of CRAPIR in mice impairs cardiomyocyte proliferation and reduces heart regenerative potential.

View Article and Find Full Text PDF

Introduction: Whether the implementation of a multimodal prehabilitation program is effective and safe for high-risk heart or lung transplantation candidates, whose condition prevents hospital discharge, is unclear.

Methods: We conducted a retrospective study at a cardiothoracic transplant center in Chile. Two cohorts of hospitalized patients listed for heart or lung transplant were studied: the first underwent traditional (historical) and nonstructured prehabilitation, and the second underwent protocol-driven multimodal prehabilitation (MP).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!